发明名称 |
Methods of colchicine administration |
摘要 |
The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug. |
申请公布号 |
US8927607(B1) |
申请公布日期 |
2015.01.06 |
申请号 |
US201313973897 |
申请日期 |
2013.08.22 |
申请人 |
Hikma Pharmaceuticals LLC |
发明人 |
Ducharme Murray |
分类号 |
A61K31/506;A61K31/4196;A61K31/4164;A61K31/138;A61K31/165 |
主分类号 |
A61K31/506 |
代理机构 |
Troutman Sanders LLP |
代理人 |
Sullivan Clark G.;Troutman Sanders LLP |
主权项 |
1. A method of treating a patient for an inflammatory disorder, wherein the inflammatory disorder is chronic gout, familial Mediterranean fever or Behçet's disease, with colchicine while concomitantly administering a second drug that is an inhibitor of the cytochrome P450 3A4 isoenzyme (CYP3A4) but is not an inhibitor of P-glycoprotein 1 (P-gp), wherein the second drug is voriconazole, fluconazole or cimetidine wherein the method comprises:
a) administering to the patient a therapeutically effective fixed maintenance dose of colchicine in an amount of from about 0.6 to about 1.2 mg/day, for a maintenance period of a plurality of days, without administering the second drug; b) after step (a), administering to the patient one or more therapeutically effective doses of the second drug; and c) concomitantly with step (b), administering to the patient the fixed maintenance dose of colchicine of step (a) without dose reduction. |
地址 |
Amman JO |